Compare Abbott Laboratories (ABT) vs MicroSectors FANG and Innovation 3X Leveraged ETN (FNGU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs MicroSectors FANG and Innovation 3X Leveraged ETN — how do they compare? Abbott Laboratories trades at $111 (market cap $187.95B), while MicroSectors FANG and Innovation 3X Leveraged ETN trades at $32.28. The key difference: Abbott Laboratories pays a 2.32% dividend while MicroSectors FANG and Innovation 3X Leveraged ETN pays none, and MicroSectors FANG and Innovation 3X Leveraged ETN is trading nearer its 52-week high, Abbott Laboratories nearer its low. Which is the better fit depends on your goals.
| ABT | FNGU | |
|---|---|---|
Market Cap | $187.95B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $136.62 | $36.15 |
52-Week Low | $82.57 | $13.73 |
Enterprise Value | $214.96B | — |
Dividend Yield | 2.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.
Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.
FNGU, a 3X leveraged ETN tracking the FANG+ Index, trades at $32.19, down 4.48% on the day, with recent volatility highlighted by a 16% single-session drop on June 5, 2026. Technical indicators show a bullish moving average signal but overbought RSI levels, with key support at $32 and resistance at $34. The product's inherent leverage amplifies both gains and losses, as seen in recent performance gaps versus the underlying index.
The outlook for FNGU is highly speculative, driven by leveraged exposure to mega-cap tech stocks. Investment opportunity lies in magnified upside during strong bull markets, but risks are severe, including decay from daily rebalancing and extreme volatility. Investors face potential rapid capital erosion in downturns, as evidenced by recent sharp declines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About MicroSectors FANG and Innovation 3X Leveraged ETN
FNGU is a leveraged ETN that seeks to provide three times (3x) the daily performance of top tech and innovation stocks. It is intended for traders seeking magnified short-term returns.
Read more on FNGU →
